<DOC>
	<DOCNO>NCT02916316</DOCNO>
	<brief_summary>All patient enrol study treat chemo immunotherapy scheme R-CHOP doxorubicin , doxorubicin analogue non pegylated liposomal anthracycline ( R-COMP ; Sec . 648 DM ) administer every 21 day 6 cycle . In unfavourable patient ( stage II-IV ) allow 2 additional cycle rituximab end 6 cycle R-CHOP .</brief_summary>
	<brief_title>Study Investigating Cardiotoxicity Anthracyclines Patients With Diffuse Large B-Cell</brief_title>
	<detailed_description>The study design prospective observational multicenter study evaluate role possible early marker cardiotoxicity estimate overall maximum risk equal 20 % patient . The sample size , require obtain estimate conventional anthracycline cardiotoxicity population , calculate confidence interval 95 % maximum acceptable error ± 0.075 . According condition describe , sample size patient treat conventional anthracycline result 124 patient . Considering 10-15 % evaluable patient , sample size fix 150 patient treat R-CHOP . The duration enrollment phase define 2 year . With sample size possible ass risk cardiotoxicity relate predictor worst group frequency least 10 % .</detailed_description>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Histologically confirm Diffuse Large BCell Lymphoma diagnosis Patient eligible receive 6 cycle RCHOP RCHOP like chemotherapy full dose Age ≥ 18 Stage IIV Written inform consent ECOG Performance Status 03 Ventricular Ejection Fraction ( VEF ) ≥40 % No previous treatment lymphoma ( except RTIF ) Negative βHCG pregnancy test result diagnosis female childbearing potential Use acceptable method contraception study 3 month receive last dose study drug patient childbearing potential Availability patient follow phase chemotherapy treatment subsequent followup Inability schedule treatment full dose chemoimmunotherapy RCHOP RCHOPlike different reason Central nervous system involvement due lymphoma HIV Active cardiac pathology include heart failure , leave ventricular dysfunction document LVEF &lt; 40 % , arrhythmia ( rapid atrial fibrillation , frequent ventricular arrhythmia ) , valvular aortic mitral disfunction &gt; moderate , ischemic heart disease ( myocardial infarction acute coronary syndrome 6 month , angina rest mild effort ) Previous treatment lymphoma Other malignancy 3 year prior diagnosis lymphoma exception nonmelanoma skin cancer situ carcinoma Any coexist medical condition would preclude participation study ( uncontrolled bacterial viral fungal infection ) Pregnant , lactate breastfeed female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Large B-Cell</keyword>
	<keyword>Cardiotoxicity</keyword>
</DOC>